The trajectory of Sildenafil presents a challenging picture for shareholders. While the initial release generated significant gains, the end of its exclusive rights opened the avenue to generic versions, dramatically https://bookmarksoflife.com/story7376113/sildenafil-and-the-pharmaceutical-industry-a-precarious-bet